RSV vaccine race heats up with highly effective GSK shot
Data unveiled on Thursday showed GSK’s GSK.L respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults.
RSV is a leading cause ...